Search This Blog

Friday, November 1, 2019

Waves of Cerebrospinal Fluid Flow Into the Brain During Sleep

A high amplitude EEG is highlighted in red of a patient during Slow Wave Sleep
The brain’s cerebrospinal fluid (CSF) pulses during deep sleep and this appears to be tied to brain wave activity and blood flow, an exploratory study showed.
Large oscillations of CSF inflow to the brain appeared about every 20 seconds and were tightly coupled to functional magnetic resonance imaging (fMRI) signals of blood flow and electroencephalogram (EEG) slow waves, reported Laura Lewis, PhD, of the Boston University College of Engineering, and co-authors, who described this activity for the first time in Science.
“We’ve known for a while that there are these electrical waves of activity in the neurons,” Lewis said in a statement. “But before now, we didn’t realize that there are actually waves in the CSF, too.”
“It’s such a dramatic effect,” she added. “Now we can just glance at one brain region and immediately have a read-out of the brain state someone’s in.”
During sleep, the brain shows large-scale waves: waves of blood oxygenation (red), followed by waves of cerebrospinal fluid (blue). Copyright Laura Lewis, Boston University.
The findings may have implications for neurodegenerative diseases, including Alzheimer’s disease and dementia. Recent studies have shown that tau and amyloid beta levels were tied to sleep and that slow wave activity during non-REM sleep was inversely related to Alzheimer’s pathology.
“Disturbances of slow wave sleep commonly accompany aging, major depressive disorders, and dementia,” noted Soren Grubb, PhD, and Martin Lauritzen, MD, both of the University of Copenhagen in Denmark, in an accompanying editorial.
“It will be interesting to assess whether the CSF dynamics linked to slow wave sleep can be used as a biomarker for disease states and whether strategies that restore slow wave sleep can rescue brain function in neurodegeneration,” Grubb and Lauritzen wrote.
In their study, Lewis and colleagues simultaneously measured blood oxygen level–dependent (BOLD) fMRI dynamics, EEG, and CSF flow simultaneously in 13 young people during sleep. They acquired fMRI data at fast rates to detect fluid inflow: fresh fluid arriving at the edge of the imaging volume has high signal intensity because it has not yet experienced radiofrequency pulses, the team noted.
EEG, BOLD, and CSF signals displayed a specific timing sequence during slow wave sleep, with neural rhythms preceding BOLD signals and CSF waves. “The neural change always seems to happen first, and then it’s followed by a flow of blood out of the head, and then a wave of CSF into the head,” Lewis said. It’s not clear how the waves are related to each other, but one explanation may be that when neurons shut off, they don’t require as much oxygen, so blood leaves and CSF quickly flows in to maintain pressure in the brain, she noted. “But that’s just one possibility,” she said.
The results address a key question in sleep neurophysiology about CSF and waste clearance, the researchers noted. “Neurovascular coupling has been proposed to contribute to clearance, but why it would cause higher clearance rates during sleep was not known,” they wrote. “Our study suggests slow neural and hemodynamic oscillations as a possible contributor to this process, in concert with other physiological factors.”
Studies in animals could test for causal relationships, the team suggested. And because the people studied in this research were ages 23 to 33 years, the researchers plan to recruit older adults next to see how aging might affect blood and CSF flow during sleep.
Last Updated November 01, 2019
This work was supported by the National Institutes of Health and the Martinos Center for Biomedical Imaging.
Several members of the research team are inventors on a provisional patent cover sheet.
The editorialists are supported by the Lundbeck Foundation and the Independent Research Fund Denmark.

In a bid to get to Chinese patients faster, Shanghai’s I-Mab plans $100M Nasdaq IPO

Aiming to be the next Chinese company to list on Nasdaq after Zai Lab’s debut two years ago, the Shanghai drug developer I-Mab is gunning for a $100 million IPO.
The company — which has raised more than $400 million in the last three years — has a shrewd strategy for biologic development: it first conducts its proof-of-concept trials in the United States and works towards getting FDA clearance for in-human studies.  The data generated are then used to advance clinical development in China. Eventually, after the experimental drug has been clinically validated in the United States, the company retains Chinese rights for further development and commercialization — while retaining the option to out-license globally.
I-Mab’s approach could allow Chinese patients to access treatments concurrently or soon after their market approvals elsewhere, particularly since Chinese officials have carved out a pathway for the fast-track approval of drugs supported by solid overseas clinical data and granted priority reviews. Zai Lab, which has acquired a slate of late-stage and commercial products to quickly build its portfolio, has benefited from these Chinese reforms.
I-Mab, meanwhile, has a slate of ten clinical and preclinical biologics for autoimmune disease and cancer, which is on the rise in China due to pollution and lofty rates of smoking. Growth in China’s biologics market has surpassed the global biologics market and is expected to reach $189.4 billion in sales by 2030, I-Mab said, citing a Frost & Sullivan report.
The company’s global portfolio houses monoclonal antibodies and bi-specific antibodies. Three drugs: TJM2, TJC4 and TJD5 are in phase 1 trials in the United States — and applications to test TJC4 and TJD5 in humans was granted by China’s National Medical Products Administration (NMPA) earlier this year.
In its China portfolio, the company has five home-grown investigational drugs that are in or ready for phase II or phase III trials in China, having met the related pre-set safety and preliminary efficacy endpoints in early or mid-stage studies in Europe or the United States. TJ202 is in two pivotal trials testing its use in multiple myeloma in Taiwan, while the NMPA has endorsed testing the drug for the same indications in humans in China. Data on TJ101 is being compiled for an application to test in a registrational trial in China. For enoblituzumab, an IND is being prepped for 2020 for a mid-stage trial or a pivotal trial. Altogether, the company is vying to submit a slate of marketing applications come 2021.
The company was established in June 2016 and has inked a number of collaborations, including MorphoSys, Genexine, MacroGenics, and Ferring. It intends to list on the Nasdaq with the symbol IMAB.

Trump taps MD Anderson’s Stephen Hahn as new FDA commish

Stephen Hahn’s nomination as the new commissioner of the FDA was delivered right on schedule Friday, with the clock ticking down on the November 1 deadline President Donald Trump faced in finding a permanent replacement for Scott Gottlieb. The pending news had become the worst kept secret in Washington. But the full meaning of the move is still undetermined.
The Chief Medical Executive at MD Anderson had a rep for steering straight into confrontation, when the future of the institution was at stake. More problematic, perhaps, will be his role in dismissing Chinese researchers at a time the Trump administration has been bearing down on the Asian giant. Just how Hahn will manage drug development, which is my primary arena of interest, is going to take some time to figure out.
Interim chief Ned Sharpless was the clear institutional favorite for getting the job full time after a stint at the NCI. Patient groups loved him and the industry deeply respected his expertise, even if he never generated the kind of enthusiasm Scott Gottlieb achieved at the agency’s helm as the first commissioner with real celebrity status.
___________________________________________________________________________________
FDA Commissioner
✔
@FDACommissioner
· 1h
It has been a privilege to serve as the Acting Commissioner since April. Working among so many passionate, talented and smart people at the FDA has been an experience I will cherish. https://twitter.com/SecAzar/status/1190341095760257027 …
Secretary Alex Azar
✔
@SecAzar
I’m pleased that @POTUS has announced his intent to nominate Stephen Hahn to lead the @US_FDA. Stephen is a talented, experienced leader whose scientific accomplishments make him well prepared to lead FDA in its vital public health mission.
FDA Commissioner
✔
@FDACommissioner
As the process to confirm Dr. Hahn begins, I will return to @theNCI to resume my role as @NCIDirector. I am confident Dr. Hahn will provide strong leadership for the FDA. https://twitter.com/SecAzar/status/1190341373758705665 …
Secretary Alex Azar
✔
@SecAzar
Replying to @SecAzar and 2 others
We also thank Dr. Ned Sharpless for his work as Acting Commissioner. He has done an exemplary job, and I look forward to continuing to work with him as he works on key priorities at @theNCI, such as pediatric cancer and rural cancer care.
8
4:37 PM – Nov 1, 2019
_____________________________________________________________
Hahn’s nomination, though, won’t trigger any obvious backlash in biopharma. As a respected executive at MD Anderson with a track record in research and a career in oncology that extended back through a stint at the prestigious University of Pennsylvania’s Perelman School of Medicine, he’ll be expected to maintain the gold standard in drug development.
Margaret Foti, chief executive officer of AACR, set the tone with a prepared comment for the occasion:
Dr. Hahn, who is board certified in both radiation and medical oncology, is esteemed for the breadth and depth of his scientific knowledge and expertise, and he has consistently advocated for a drug review process at the FDA that is both science-directed and patient-focused.
The question is whether he’ll keep pushing the envelope on greater regulatory flexibility that has helped revolutionize cancer drug development and changed the dynamics of R&D.
That’s something no one seems to know much about. But they’ll get a chance to hear much more once the Senate picks up the nomination.

Y-mAbs Flags Potential Delay In Pre-BLA Meeting, Hues To Regulatory Timeline

Y-mAbs Therapeutics, Inc YMAB 5.62%, a thinly traded small-cap oncology-focused biopharma company, said in a Friday SEC  filing that its omburtamab pre-BLA meeting with the FDA may now be delayed.

What Happened

Y-mAbs develops novel antibody therapeutics for oncology targets based on technology licensed from Memorial Sloan Kettering Cancer Center.
The company said in the SEC filing that it received an email notification from the FDA Thursday stating that, upon reviewing the omburtamab pre-BLA meeting submission, the regulatory body deemed that the pre-BLA meeting originally scheduled for November will now be converted into a general guidance meeting,

The New York-based company said the FDA did not indicate a reason for the change.

Why It’s Important

Omburtamab is an antibody that is broadly reactive with human solid tumors. It is being evaluated for multiple indications, with CNS/leptomeningeal metastases from neuroblastoma in pediatric patients in the most advanced stage of development.
Y-mAbs said its rolling submission for omburtamab, which was originally planned to commence in December, may not take place in 2019. It could now be rescheduled to the first quarter of 2020, the company said.
“We remain confident in the contents of our pre-BLA meeting submission and do not believe that this change in the timing of the pre-BLA meeting with the FDA will impact our previously disclosed and anticipated timing for our complete omburtamab BLA submission, which we still expect to complete by the end of the first quarter of 2020,” Y-mAbs said.
The company said it hopes to have flexibility to file the BLA, either via a rolling submission or a single submission.
The commercialization timeline is unaffected, according to Y-mAbs.
On Oct 26, the company presented updated data for omburtamab at the International Society of Pediatric Oncology Annual Congress in Lyon, France that showed an improvement in median survival from 47.1 months at the prior readout to 50.8 months.

What You Need To Know About Warren’s Plan To Pay For ‘Medicare For All’

Democratic presidential candidate Sen. Elizabeth Warren proposed Friday to pay for a “Medicare for All” health care system without raising taxes on most people.
Warren said she could raise more than $20 trillion over a decade for the system through charges levied on large employers, a wealth surtax on billionaires and a new tax on financial transactions like stock and bond trades.
Warren has been under pressure to explain how she’d pay for the proposal under which private insurance would be eliminated and all Americans would get health care through a government system focused on whether patients need the care rather than whether they can afford it.

What You Need to Know About The Spending Proposal

The tax proposal would:
  • Have employers pay the government (instead of insurers) most of what they currently pay for health insurance – raising nearly $9 trillion over a decade.
  • Raise $800 billion over a decade through a tax of one-tenth of 1% on the sale of bonds, stocks or derivatives.
  • Raise $2.9 trillion through changes in corporate tax collection laws.
  • Raise $1 trillion through a 6% tax on individual net worth above $1 billion.
  • Raise $100 billion through a fee on the largest banks.
  • Raise $2 trillion by taxing non-retirement account capital gains annually on the the top 1% of households.
  • Boost tax collections by $2.3 trillion through stronger enforcement.
The rest Warren said would come through stronger enforcement of the existing tax code, higher collections of existing taxes due to higher take-home incomes and other efficiencies.
“Under my Medicare for All plan, costs will go up for the very wealthy and big corporations, and costs will go down for middle-class families,” Warren said in her policy paper on the proposal. “I will not sign a bill that violates these commitments.”

Gilead to up stake in Galapagos to 25.1%

An affiliate of Gilead Sciences (NASDAQ:GILD) has notified Galapagos NV (NASDAQ:GLPG) that it will exercise the Initial Warrant A, approved by GLPG shareholders on October 22, allowing Gilead to increase its ownership stake to over 25%.
Under the terms of the warrant, Gilead will subscribe for 2,617,791 new shares at €140.59 per share for a total of €368,035,236.69, raising its ownership to 16,207,477 GLPG shares, representing 25.1% of the 64,571,622 shares expected to be outstanding after exercise.
Gilead upped its stake from 12.3% to 22% in July in conjunction with its 10-year R&D deal with GLPG.

Biohaven Pharmaceuticals EPS misses by $0.54

Biohaven Pharmaceuticals (NYSE:BHVN): Q3 GAAP EPS of -$2.04 misses by $0.54.
Cash balance of $416.6M